PCM
AMLX icon

Prelude Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Prelude Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,600
Closed -$304K – 1115
2023
Q3 		$304K Buy
16,600
+6,500
+64% +$137K 0.02% 668
2023
Q2 		$218K Buy
10,100
+2,800
+38% +$75.6K 0.01% 806
2023
Q1 		$214K Buy
+7,300
New +$254K 0.01% 830

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's AMLX Position: Q4 2023 in Review

Prelude Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 16,600 shares — an estimated $304K sold.

Prelude Capital Management first reported a position in AMLX in Q1 2023 and held it in 3 quarters. The position peaked at $304K in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Prelude Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 16,600 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $304K.
  • Prelude Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Prelude Capital Management's Amylyx Pharmaceuticals position peaked at $304K in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.